The maximum anti-tumor activity of ESK981 against prostate cancer was observed in immunocompetent tumor environments where activation of interferon gamma pathway by ESK981 enhanced the expression of inflammatory chemokine CXCL10 that led to functional T-cell infiltration, thereby synergizing the therapeutic response to the immune checkpoint blockade [9]. The gene discussed is IFNG; the disease is neoplasm.